Canine atopic dermatitis and other chronic skin conditions cause persistent itching and discomfort affecting millions of dogs, with newer biological therapies offering dramatically improved welfare outcomes.
Canine atopic dermatitis causes chronic, intense pruritus that significantly impairs quality of life. Dogs with poorly controlled atopic dermatitis scratch and chew constantly, disrupting sleep, preventing normal activities, and causing progressive self-trauma that leads to secondary infections. The welfare burden accumulates over the lifetime of the disease — often years to decades — creating continuous suffering that owners often normalize as the dog personality rather than as manageable chronic pain. The development of targeted biological therapies has transformed the welfare outlook for atopic dogs. Oclacitinib and lokivetmab achieve rapid, effective itch control with minimal side effects, enabling comfortable daily life for most affected dogs. Early diagnosis and implementation of effective management prevents the chronic secondary infections and skin changes that come from years of inadequate control.